Treatment of advanced Parkinson's disease with intraduodenal levodopa infusion;Kontinuerlig behandling med levodopa ved Parkinsons sykdom

Tidsskrift for den Norske Laegeforening

Volumn 125, Issue 19, 2005, Pages 2638-2640

  Lundqvist, Christofer ^a,b,c   Nystedt, Trond ^c   Reiertsen, Ola ^c   Grotli, Ragnvald ^c   Beiske, Antonie Giæver ^c  

^a Nevrologisk Avdeling   (Norway)

^b ULLEVÅL UNIVERSITY HOSPITAL   (Norway)

^c AKERSHUS UNIVERSITY HOSPITAL   (Norway)

Author keywords

[No Author keywords available]

Indexed keywords

DUODOPAR; LEVODOPA;

ARTICLE; CLINICAL ARTICLE; HUMAN; PARKINSON DISEASE; PILOT STUDY; TREATMENT OUTCOME;

AGED; ANTIPARKINSON AGENTS; CARBIDOPA; DRUG COMBINATIONS; DUODENUM; HUMANS; INFUSION PUMPS; LEVODOPA; MIDDLE AGED; PARKINSON DISEASE;

EID: 26944475178     PISSN: 00292001     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (19)

1. Ahlskog JE, Muenter M. Frequency of levodopa-related dyskinesias and motor fluctuations as estimated from the cumulative literature. Mov Disord 2001; 16: 448-58.
2. Stocchi F, Olanow CW. Continuous dopaminergic stimulation in early and advanced Parkinson's disease. Neurology 2004; 62: S56-S63.
3. Deuschl G, Wenzelburger R, Kopper F et al. Deep brain stimulation of the subthalamic nucleus for Parkinson's disease: a therapy approaching evidence-based standards. J Neurol 2003; 250 (suppl 1):143-16.
4. Lagrange E, Krack P, Moro E et al. Bilateral subthalamic nucleus stimulation improves health-related quality of life in PD. Neurology 2002; 59: 1976-8.
5. Herzog J, Volkmann J, Krack P et al. Two-year follow-up of subthalamic deep brain stimulation in Parkinson's disease. Mov Disord 2003; 18: 1332-7.
6. Stocchi F, Vacca L, De Pandis MF et al. Subcutaneous continuous apomorphine infusion in fluctuating patients with Parkinson's disease: long-term results. Neurol Sci 2001; 22: 93-4.
7. Di Rosa AE, Epifanio A, Antonini A et al. Continuous apomorphine infusion and neuropsychiatric disorders: a controlled study in patients with advanced Parkinson's disease. Neurol Sci 2003; 24: 174-5.
8. Shoulson I., Glaubiger GA, Chase TN. On-off response. Clinical and biochemical correlations during oral and intravenous levodopa administration in parkinsonian pasients. Neurology 1975; 25: 1144-8.
9. Quinn N, Parkes JD, Marsden CD. Control of on/ off phenomenon by continuous intravenous infusion of levodopa. Neurology 1984; 34: 1131-6.
10. Sage JI, Schuh L, Heikkila RE et al. Continuous duodenal infusions of levodopa: plasma concentrations and motor fluctuations in Parkinson's disease. Clin Neuropharmacol 1988; 11: 36-44.
11. Schuh LA, Bennett JP jr. Suppression of dyskinesias in advanced Parkinson's disease. I. Continuous intravenous levodopa shifts dose response for production of dyskinesias but not for relief of parkinsonism in patients with advanced Parkinson's disease. Neurology 1993; 43: 1545-50.
12. Nilsson D, Hansson LE, Johansson K et al. Long-term intraduodenal infusion of a water based levodopa-carbidopa dispersion in very advanced Parkinson's disease. Acta Neurol Scand 1998; 97: 175-83.
13. Bredberg E, Nilsson D, Johansson K et al. Intraduodenal infusion of a water-based levodopa dispersion for optimisation of the therapeutic effect in severe Parkinson's disease. Eur J Clin Pharmacol 1993; 45: 117-22.
14. Nilsson D, Nyholm D, Aquilontus SM. Duodenal levodopa infusion in Parkinson's disease - long-term experience. Acta Neurol Scand 2001; 104: 343-8.
15. Nyholm D, Askmark H, Gomes-Trolin C et al. Optimizing levodopa pharmacokinetics: intestinal infusion versus oral sustained-release tablets. Clin Neuropharmacol 2003; 26: 156-63.
16. Nyholm D, Nilsson Remahl AIM, Dizdar N et al. Duodenal levodopa infusion monotherapy vs oral polypharmacy in advanced Parkinson disease. Neurology 2005; 64: 216-23.
17. Tandberg E, Larsen JP, Nessler EG et al. The epidemiology of Parkinson's disease in the county of Rogaland, Norway. Mov Disord 1995; 10: 541-9.
18. Hughes AJ, Daniel SE, Kilford L et al. Accuracy of clinical diagnosis of idiopathic Parkinson's disease: a clinico-pathological study of 100 cases. J Neurol Neurosurg Psychiatry 1992; 55: 181-4.
19. Dodel RC, Berger K, Oertel WH. Health-related quality of life and healthcare utilisation in patients with Parkinson's disease: impact of motor fluctuations and dyskinesias. Pharmacoeconomics 2001; 19: 1013-38.